BioAge, IPO
Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 million in its initial public offering and a private placement.
Obesity drug developer BioAge seeks up to $587 mln valuation in US IPO
Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory filing.
Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO
Obesity drug developer BioAge Labs (BIOA) has filed regulatory filings as part of its U.S. IPO. It seeks to offer 7.5M shares at a price range of $17 to $19, implying a valuation of up to $602M at the midpoint. Sofinnova Venture Partners, a leading BioAge ...
Obesity drugmaker BioAge targets $158 million in IPO
The company is offering 7.5 million shares for $17 to $19 apiece, according to a filing Wednesday
Drugmaker seeks $157.5M in IPO, placement
BioAge Labs, a clinical-stage biotech firm focused on obesity and metabolic disease therapies, aims to raise up to $157.5 million through its initial public offering and private placement, Bloomberg reported Sept. 18. The company plans to offer 7.5 million shares priced between $17 and $19 each, according to a filing with the Securities and Exchange Commission. At the top of the price range, BioAge's market valuation could reach $587 million. Previously, the company had a valuation of $394 million after raising $194 million in a Series D funding round in February.
Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO
Obesity drug developer BioAge Labs (BIOA) has filed regulatory filings as part of its U.S. IPO. It seeks to offer 7.5M shares at a price range of $17 to $19, implying a valuation of up to $602M at ...
Ziarul BURSA | BURSA.RO8h
BioAge wants to raise $158 million through IPO
BioAge Labs Inc., an American clinical-stage biotech company developing therapies for obesity and metabolic diseases, is ...
ETF Daily News5d
BioAge Labs Inc. (BIOA) Plans to Raise $135 Million in September 26th IPO
BioAge Labs Inc. (BIOA) is planning to raise $135 million in an initial public offering on Thursday, September 26th, IPO Scoop reports. The company will issue 7,500,000 shares at a price of $17.00 ...
AOL18d
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering.
Seeking Alpha17d
BioAge Labs Readies $100 Million IPO Plan For Obesity Treatment
A Quick Take On BioAge Labs, Inc. BioAge Labs, Inc. (BIOA) has filed to raise $100 million in an IPO of its common stock, according to SEC S-1 registration information. The company is a clinical ...
Capital Markets
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...
Yahoo Finance4d
Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
(Bloomberg) -- BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 million in its initial public ...
Yahoo3d
Obesity drug developer BioAge seeks up to $587 million valuation in US IPO
(Reuters) - Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a ...
Health News | Today's Latest Stories | Reuters
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...